![]() |
市場調查報告書
嵌合抗原受體 (CAR) T細胞免疫療法:競爭情形,技術,開發平台分析Chimeric Antigen Receptor (CAR) T Cell Immunotherapy - Competitive Landscape, Pipeline and Market Analysis, 2018 |
||||||
出版商 | DelveInsight Business Research LLP | 商品編碼 | 524520 | ||||
出版日期 | 按訂單生產 | 內容資訊 | 英文 289 Pages 商品交期: 10個工作天內 |
||||
價格 |
|
嵌合抗原受體 (CAR) T細胞免疫療法:競爭情形,技術,開發平台分析 Chimeric Antigen Receptor (CAR) T Cell Immunotherapy - Competitive Landscape, Pipeline and Market Analysis, 2018 | ||
出版日期: 按訂單生產 | 內容資訊: 英文 289 Pages |
|
本報告提供嵌合抗原受體 (CAR) T細胞免疫療法調查分析,以上市、開發平台藥物為焦點,提供開發平台的競爭情形,上市藥的資訊,現在、未來市場,開發中產品,主要企業等系統性資訊。
"Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Pipeline and Market Analysis, 2018", report provides comprehensive Insight about marketed and pipeline drugs across this Immunotherapy. The report provides the detailed analysis of 190+ products along with 60+ companies involved. Celgene Corporation and bluebird bio has been granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for bb2121 Anti-BCMA CAR-T Cell Therapy for Relapsed and Refractory Multiple Myeloma.
Products covered by Phase
Overview of pipeline development activities for Chimeric Antigen Receptor (CAR) T cell Immunotherapy
Pipeline analysis of 190+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details. Report contains the development and sale activities for marketed drugs.
Therapeutic segmentation of products for Chimeric Antigen Receptor (CAR) T cell Immunotherapy
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this Immunotherapy.
Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Overview
Chimeric antigen receptor (CAR) T-cells
History
CARs and Generations
Advantages of CAR-T cells
Adverse Events with CAR T-cell Therapy
Limitations of Existing Technologies for CAR T-Cells
Marketed Products
Kymriah: Novartis
Product Description
Regulatory Milestones
Research and Development
Other Clinical Activities
Product Development Activities
Pipeline Therapeutics
Clinical Phase Products
Non-Clinical Phase Products
Competitive Landscape
Comparative Analysis
Mid Stage Products (Phase II)
Comparative Analysis
AU105: Aurora BioPharma
Product Description
Research and Development
Product Development Activities
(The list continues)
Early Stage Products (Phase I)
Comparative Analysis
IND Stage Products
Comparative Analysis
Unknown Stage Products
Comparative Analysis
Pre-clinical and Discovery Products
Comparative Analysis
Therapeutic Assessment : Clinical Phase Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Appendix